Premium
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor
Author(s) -
Wierda William G.,
Byrd John C.,
Davids Matthew S.,
Furman Richard R.,
Cheson Bruce D.,
Barr Paul M.,
Eradat Herbert,
Heffner Leonard,
Zhou Lang,
Verdugo Maria,
Potluri Jalaja,
Choi Michael
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15666
Subject(s) - ibrutinib , venetoclax , idelalisib , chronic lymphocytic leukemia , ofatumumab , medicine , discontinuation , oncology , leukemia
The additive effect of HC to other agents was first reported in an animal model treated with HC and recombinant erythropoietin (Al-Khatti et al, 1988) and a similar observation was made in SCD patients (Rodgers et al, 1993). Our observation makes the case to incorporate sirolimus, and probably other mTOR inhibitors, in post-transplantation immunosuppressive regimens to prevent rejection in patients with SCD. However, more studies are needed before sirolimus and other mTOR inhibitors can be recommended for SCD patients.